SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 76.92 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2025-03-26
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2024-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-12-31 was 41.19K shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-09-30 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-06-30 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2024 was 76.92K shares, a 86.74% increase from fiscal 2023.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2023 was 41.19K shares, a 76.80% decline from fiscal 2022.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2022 was 177.54K shares, a 3450.72% increase from fiscal 2021.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 5.00K shares, a 0.00% change from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 76.92K shares 10-K · filed 2025-03-26 | |||
| 2024-09-30 | 76.92K shares 10-Q · filed 2024-11-06 | ||||
| 2023-12-31 | 41.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 41.19K shares derived: sum of 2 quarters · filed 2025-03-26 | 41.19K shares derived: sum of 3 quarters · filed 2025-03-26 | 41.19K shares 10-K · filed 2025-03-26 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-16 | 0.00 shares derived: sum of 2 quarters · filed 2024-01-16 | 0.00 shares 10-Q · filed 2024-01-16 | ||
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | 0.00 shares 10-Q · filed 2023-08-18 | |||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | 177.54K shares 10-K · filed 2024-04-22 | 2.66M shares 10-K · filed 2023-03-27 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 5.00K shares 10-K · filed 2023-03-27 | |||
| 2021-09-30 | 5.00K shares 10-Q · filed 2021-10-25 | ||||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 5.00K shares 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 5.00K shares 10-Q · filed 2020-10-26 | ||||
| 2019-12-31 | 50.00K shares 10-K · filed 2021-03-29 | ||||
| 2018-12-31 | 96.18K shares 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |